Hypercitricemia in Human Cancer: Factors Concerned in Pathogenesis and Treatment
1960

Hypercitricemia in Human Cancer

Sample size: 358 publication 30 minutes Evidence: moderate

Author Information

Author(s): H. M. Lemon, J. H. Mueller, J. M. Looney, W. H. Chasen, Marcia Kelman

Primary Institution: Boston University School of Medicine

Hypothesis

Is hypercitricemia a common abnormality in untreated advanced cancer patients?

Conclusion

Hypercitricemia is frequently observed in patients with advanced cancer, particularly those with breast, prostate, and lung cancers.

Supporting Evidence

  • Hypercitricemia was found in 23.6% of cancer patients studied.
  • Women with untreated metastatic breast cancer had significantly higher citrate levels than healthy volunteers.
  • Prednisone therapy reduced elevated blood citric acid levels to normal in breast cancer patients.

Takeaway

People with certain types of cancer have higher levels of citric acid in their blood, which might be linked to how their bodies process energy.

Methodology

Citrate concentration in blood was measured using the pentobromoacetone method, with samples taken from patients and healthy volunteers after fasting.

Potential Biases

Potential bias in patient selection and the influence of prior treatments on citrate levels.

Limitations

The study may not account for all variables affecting citrate levels, and the sample may not represent all cancer types.

Participant Demographics

Included 358 individuals: healthy volunteers, patients with benign diseases, and various cancer patients across all stages.

Statistical Information

P-Value

<0.001

Confidence Interval

95%

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication